C
Cocrystal Pharma, Inc.
COCPCIK 0001412486NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-8.80M
Total Assets
$9.71M
Equity
$6.33M
Shares Out
13.79M
Op. Cash Flow
$-8.20M
Business
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel small molecule antiviral therapeutics for serious and chronic RNA viral diseases. It develops first- and best-in-class direct-acting antiviral drug candidates, including oral and inhaled influenza PB2 inhibitors, a pan-viral norovirus/coronavirus protease inhibitor (CDI-988), and HCV NS5B polymerase inhibitors. The Company operates as a single business entity focused on structure-based drug design, X-ray crystallography and computational chemistry. Its products are developed through preclinical and clinical programs and tested in regulated markets including the U.S., U.K., Australia and other international jurisdictions.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 5 | 13 | 15 | 12 | 9 | |
| General and administrative | 4 | 5 | 6 | 6 | 5 | |
| Total operating expenses | 9 | 18 | 19 | 39 | 14 | |
| Loss from operations | −9 | −18 | −19 | −39 | −14 | |
| Interest income, net | 134,000 | 537,000 | 640,000 | — | — | |
| Foreign exchange gain (loss) | 54,000 | −163,000 | −65,000 | −18,000 | −9,000 | |
| Total other income, net | 188,000 | 374,000 | 575,000 | −8,000 | 36,000 | |
| Net loss | −9 | −18 | −18 | −39 | −14 | |
| Net loss per common share, basic | −0.78 | −1.72 | −1.87 | −4.77 | −0.16 | |
| Net loss per common share, diluted | −0.78 | −1.72 | −1.87 | −4.77 | — | |
| Weighted average number of common shares outstanding, basic | 11 | 10 | 10 | 8 | 7 | |
| Weighted average number of common shares outstanding, diluted | 11 | 10 | 10 | 8 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 7 | 10 | 26 | 37 | 59 | |
| Restricted cash | 75,000 | 75,000 | 75,000 | 75,000 | 50,000 | |
| Tax credit receivable | 706,000 | 1 | 890,000 | 716,000 | — | |
| Prepaid expenses and other current assets | 328,000 | 430,000 | 2 | 2 | 568,000 | |
| Total current assets | 8 | 12 | 29 | 40 | 59 | |
| Property and equipment, net | 93,000 | 153,000 | 271,000 | 342,000 | 453,000 | |
| Deposits | 95,000 | 29,000 | 46,000 | 46,000 | 46,000 | |
| Operating lease right-of-use assets, net (including $152 and $42 to related party) | 1 | 2 | 2 | 274,000 | 478,000 | |
| Total assets | 10 | 13 | 31 | 41 | 79 | |
| Accounts payable and accrued expenses | 2 | 2 | 3 | 976,000 | 1 | |
| Current maturities of operating lease liabilities (including $49 and $42 to related party) | 334,000 | 301,000 | 240,000 | 233,000 | 209,000 | |
| Total current liabilities | 2 | 2 | 3 | 1 | 2 | |
| Operating lease liabilities (including $104 and $0 to related party) | 1 | 2 | 2 | 57,000 | 291,000 | |
| Total long-term liabilities | 1 | 2 | 2 | 57,000 | 298,000 | |
| Total liabilities | 3 | 4 | 5 | 1 | 2 | |
| Commitments and contingencies | — | — | — | — | — | |
| Common stock $0.001 par value; 100,000 and 150,000 shares authorized as of December 31, 2025 and 2024, respectively; 13,784 and 10,174 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 13,000 | 10,000 | 10,000 | 8,000 | 8,000 | |
| Additional paid-in capital | 349 | 343 | 342 | 337 | 337 | |
| Accumulated deficit | −342 | −333 | −316 | −298 | −259 | |
| Total stockholders equity | 6 | 10 | 26 | 40 | 78 | |
| Total liabilities and stockholders equity | 10 | 13 | 31 | 41 | 79 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization expense | 72,000 | 126,000 | 189,000 | 185,000 | 190,000 | |
| Right of use assets | 304,000 | 320,000 | −2 | 203,000 | — | |
| Stock-based compensation | 270,000 | 643,000 | 801,000 | 855,000 | 724,000 | |
| Change in operating lease liabilities | −301,000 | −210,000 | 2 | −209,000 | — | |
| Tax credit receivable | 509,000 | −325,000 | −174,000 | — | — | |
| Prepaid expenses and other current assets | 102,000 | 1 | 470,000 | −2 | −169,000 | |
| Deposits | −66,000 | 17,000 | — | — | — | |
| Accounts payable and accrued expenses | −251,000 | −895,000 | 2 | −321,000 | −217,000 | |
| Net cash used in operating activities | −8 | −16 | −15 | −21 | −13 | |
| Purchases of property and equipment | −12,000 | −8,000 | −118,000 | −74,000 | −52,000 | |
| Net cash used in investing activities | −12,000 | −8,000 | −118,000 | −74,000 | −52,000 | |
| Proceeds from the sale of common stock under ATM | 154,000 | — | 4 | — | 39 | |
| Proceeds from sale of common stock and warrants, net of transaction costs | 5 | — | — | — | — | |
| Net cash provided by financing activities | 5 | — | 4 | −27,000 | 38 | |
| Net decrease in cash and restricted cash | −3 | −16 | −11 | −22 | 26 | |
| Initial recognition of right-of-use assets and lease liabilities | — | 163,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro